A Food and Drug Administration (FDA) expert panel has reignited a debate over whether hormone therapy should be used to treat ...

The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and the U.K. have already cleared it for use.

The Food and Drug Administration (FDA) has extended the review period for elinzanetant, an investigational hormone-free therapy for the treatment of moderate to severe vasomotor symptoms (VMS) due to ...

The panelists said that vaginal creams and other localized therapies for menopause are safe and vastly underused by women who ...

Members of an FDA expert panel discussed reassessing boxed warnings for menopausal HT and how to better educate patients and ...

The FDA is reconsidering the black box warning on estrogen. Experts say it’s time for a change—find out what this means for ...

Simultaneously, Bayer is making significant headway with its cancer medication Sevabertinib. The company has applied for regulatory approval in China, where the drug has already received the coveted ...

A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said ...

Experts worry the warning on vaginal estrogen menopause treatments is doing more harm than good and is not supported by science.

Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) (OTCPK:BAMXF) said it has received notification from the FDA regarding an extension of the ...

Bypassing its standard pathways for scientific discussions, FDA has recently held a slew of so-called "expert panels" that ...

The debate over whether to use hormone therapy to treat menopausal women continues, as a Food and Drug Administration (FDA) expert panel weighs in. The panel, consisting […] ...